TCL Archive In Brief: Eyre ACS President, Freeman President Elects, Kathleen Horsch Chairman, Davis Heads ASTRO November 20, 1987
TCL Archive Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial December 25, 2009
TCL Archive New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB. October 8, 2004
TCL Archive DeVita On Problems Of Drug Response: There May be Tw Populations Of Cells; Molecular Medicine will Change Treatment December 13, 1991
